Novel copper(II) complex of N-propyl-norfloxacin and 1,10-phenanthroline with enhanced antileukemic and DNA nuclease activities

Journal of Medicinal Chemistry

Volumn 51, Issue 3, 2008, Pages 470-478

  Katsarou, Maria E ^a   Efthimiadou, Eleni K ^a,b   Psomas, George ^c   Karaliota, Alexandra ^b   Vourloumis, Dionisios ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

(CHLORO)(1,10 PHENANTHROLINE)(N PROPYLNORFLOXACINATO)COPPER COMPLEX; 1,10 PHENANTHROLINE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; COPPER COMPLEX; DNA; N PROPYLNORFLOXACIN; NORFLOXACIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME BINDING; ESCHERICHIA COLI; HUMAN; HUMAN CELL; LEUKEMIA; MEMBRANE STRUCTURE; METAL BINDING; PLASMID; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; COPPER; DEOXYRIBONUCLEASES; DNA, SUPERHELICAL; ESCHERICHIA COLI; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICROBIAL SENSITIVITY TESTS; NECROSIS; NORFLOXACIN; ORGANOMETALLIC COMPOUNDS; PHENANTHROLINES; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 39149114423     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7013259     Document Type: Article

References (92)

1. Koga, H.; Itoh, A.; Murayama, S.; Suzue, S.; Irikura, T. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J. Med. Chem. 1980, 23, 1358-1363.
2. Goldstein, E. J. Norfloxacin, a fluoroquinolone antibacterial agent. Classification, mechanism of action, and in vitro activity. Am. J. Med. 1987, 82, 3-17.
3. King, D. E.; Malone, R.; Lilley, S. H. New classification and update on the quinolone antibiotics. Am. Fam. Physician 2000, 61, 2741-2748.
4. Schaeffer, A. J. The expanding role of fluoroquinolones. Am. J. Med. 2002, 113 (Suppl 1A), 45S-54S.
5. Hooper, D. C.; Wolfson, J. S. The fluoroquinolones: Pharmacology, clinical uses, and toxicities in humans. Antimicrob. Agents Chemother. 1985, 28, 716-721.
6. Koyle, M. A.; Barqawi, A.; Wild, J.; Passamaneck, M.; Furness, P. D., 3rd. Pediatric urinary tract infections: The role of fluoroquinolones. Pediatr. Infect. Dis. J. 2003, 22, 1133-1137.
7. Shen, L. L.; Chu, D. T. W. Type II DNA topoisomerase as antibacterial targets. Curr. Pharm. Des. 1996, 2, 195-208.
8. Marians, K. J.; Hiasa, H. Mechanism of quinolone action. A drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J. Biol. Chem. 1997, 272, 9401-9409.
9. Chu, D. T. W. Recent development in antibacterial research. Annu. Rep. Med. Chem. 1998, 33, 141-150.
10. Cozzarelli, N. R. DNA gyrase and the supercoiling of DNA. Science 1980, 207, 953-960.
11. Chu, D. T.; Fernandes, P. B.; Claiborne, A. K.; Pihuleac, E.; Nordeen, C. W.; Maleczka, R. E., Jr.; Pernet, A. G. Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents. J. Med. Chem. 1985, 28, 1558-1564.
12. Domagala, J. M.; Heifetz, C. L.; Hutt, M. P.; Mich, T. F.; Nichols, J. B.; Solomon, M.; Worth, D. F. 1-Substituted 7-[3-[(ethylamino)methyl]-1- pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials. J. Med. Chem. 1988, 31, 991-1001.
13. Hughes, M. N. The Inorganic Chemistry of Biological Processes, 2nd ed.; Wiley: New York, 1981.
14. Turel, I. The interactions of metal ions with quinolone antibacterial agents. Coord. Chem. Rev. 2002, 232, 27-47.
15. 1H NMR studies of selective interactions of norfloxacin with double-stranded DNA. Biochem. Biophys. Res. Commun. 2003, 304, 55-59.
16. 2+ complex on DNA: A new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex. J. Med. Chem. 1995, 38, 408-424.
17. Canton, E.; Peman, J.; Jimenez, M. T.; Ramon, M. S.; Gobernado, M. In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob. Agents Chemother. 1992, 36, 558-565.
18. Wiles, J. A.; Wang, Q.; Lucien, E.; Hashimoto, A.; Song, Y.; Cheng, J.; Marlor, C. W.; Ou, Y.; Podos, S. D.; Thanassi, J. A.; Thoma, C. L.; Deshpande, M.; Pucci, M. J.; Bradbury, B. J. Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: Synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. Bioorg. Med. Chem. Lett. 2006, 16, 1272-1276.
19. Fang, K. C.; Chen, Y. L.; Sheu, J. Y.; Wang, T. C.; Tzeng, C. C. Synthesis, antibacterial, and cytotoxic evaluation of certain 7-substituted norfloxacin derivatives. J. Med. Chem. 2000, 43, 3809-3812.
20. Pfeiffer, E. S.; Hiasa, H. Replacement of ParC alpha4 helix with that of GyrA increases the stability and cytotoxicity of topoisomerase IV-quinolone-DNA ternary complexes. Antimicrob. Agents Chemother. 2004, 48, 608-611.
21. Xia, Y.; Yang, Z. Y.; Xia, P.; Bastow, K. F.; Tachibana, Y.; Kuo, S. C.; Hamel, E.; Hackl, T.; Lee, K. H. Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2′,3′,4′-substituted-1,2,3,4-tetrahydro-2- phenyl-4-quinolones as a new class of antimitotic antitumor agents. J. Med. Chem. 1998, 41, 1155-1162.
22. Kamat, A. M.; DeHaven, J. I.; Lamm, D. L. Quinolone antibiotics: A potential adjunct to intravesical chemotherapy for bladder cancer. Urology 1999, 54, 56-61.
23. Turel, I.; Golobic, A.; Klavzar, A.; Pihlar, B.; Buglyo, P.; Tolis, E.; Rehder, D.; Sepcic, K. Interactions of oxovanadium(IV) and the quinolone family member-ciprofloxacin. J. Inorg. Biochem. 2003, 95, 199-207.
24. Saha, D. K.; Sandbhor, U.; Shirisha, K.; Padhye, S.; Deobagkar, D.; Anson, C. E.; Powell, A. K. A novel mixed-ligand antimycobacterial dimeric copper complex of ciprofloxacin and phenanthroline. Bioorg. Med. Chem. Lett. 2004, 14, 3027-3032.
25. 4 chromophore. Antibacterial studies. J. Inorg. Biochem. 1995, 59, 801-810.
26. Lopez-Gresa, M. P.; Ortiz, R.; Perello, L.; Latorre, J.; Liu-Gonzalez, M.; Garcia-Granda, S.; Perez-Priede, M.; Canton, E. Interactions of metal ions with two quinolone antimicrobial agents (Cinoxacin and ciprofloxacin). Spectroscopic and X-ray structural characterization. Antibacterial studies. J. Inorg. Biochem. 2002, 92, 65-74.
27. Ruiz, M.; Perello, L.; Server-Carrio, J.; Ortiz, R.; Garcia-Granda, S.; Diaz, M. R.; Canton, E. Cinoxacin complexes with divalent metal ions. Spectroscopic characterization. Crystal structure of a new dinuclear Cd(II) complex having two chelate-bridging carboxylate groups. Antibacterial studies. J. Inorg. Biochem. 1998, 69, 231-239.
28. 2O. J. Inorg. Biochem. 1998, 71, 53-60.
29. Jimenez-Garrido, N.; Perello, L.; Ortiz, R.; Alzuet, G.; Gonzalez-Alvarez, M.; Canton, E.; Liu-Gonzalez, M.; Garcia-Granda, S.; Perez-Priede, M. Antibacterial studies, DNA oxidative cleavage, and crystal structures of Cu(II) and Co(II) complexes with two quinolone family members, ciprofloxacin, and enoxacin. J. Inorg. Biochem. 2005, 99, 677-689.
30. Drevensek, P.; Turel, I.; Poklar Ulrih, N. Influence of copper(II) and magnesium(II) ions on the ciprofloxacin binding to DNA. J. Inorg. Biochem. 2003, 96, 407-415.
31. Efthimiadou, E. K.; Thomadaki, H.; Sanakis, Y.; Raptopoulou, C. P.; Katsaros, N.; Scorilas, A.; Karaliota, A.; Psomas, G. Structure and biological properties of the copper(II) complex with the quinolone antibacterial drug N-propyl-norfloxacin and 2,2′-bipyridine. J. Inorg. Biochem. 2007, 101, 64-73.
32. Ranford, J. D.; Sadler, P. J.; Tocher, D. A. Cytotoxicity and antiviral activity of transition-metal salicylate complexes and crystal structure of bis(diisopropylsalicylato)(1,10-phenanthroline)copper(II). J. Chem. Soc., Dalton Trans. 1993, 22, 3393-3399.
33. Zoroddu, M. A.; Zanetti, S.; Pogni, R.; Basosi, R. An electron spin resonance study and antimicrobial activity of copper(II)-phenanthroline complexes. J. Inorg. Biochem. 1996, 63, 291-300.
34. Erkkila, K. E.; Odom, D. T.; Barton, J. K. Recognition and reaction of metallointercalators with DNA. Chem. Rev. 1999, 99, 2777-2796.
35. Sigman, D. S. Chemical nucleases. Biochemistry 1990, 29, 9097-9105.
36. Sigman, D. S.; Mazumder, A.; Perrin, D. M. Chemical nucleases. Chem. Rev. 1993, 93, 2295-2316.
37. Pogozelski, W. K.; Tullius, T. D. Oxidative strand scission of nucleic acids: Routes initiated by hydrogen abstraction from the sugar moiety. Chem. Rev. 1998, 98, 1089-1108.
38. Lu, L. P.; Zhu, M. L.; Yang, P. Crystal structure and nuclease activity of mono(1,10-phenanthroline) copper complex. J. Inorg. Biochem 2003, 95, 31-36.
39. Sigman, D. S.; Graham, D. R.; D'Aurora, V.; Stern, A. M. Oxygen-dependent cleavage of DNA by the 1,10-phenanthroline-cuprous complex. Inhibition of Escherichia coli DNA polymerase I. J. Biol. Chem. 1979, 254, 12269-12272.
40. Thederahn, T. B.; Kuwabara, T. A.; Larsen, D. S.; Sigman, D. S. Nuclease activity of 1,10-phenanthroline-copper: Kinetic mechanism. J. Am. Chem. Soc. 1989, 111, 4941-4946.
41. Zelenco, O.; Gallagher, J.; Sigman, D. S. Scission of DNA with bis(1,10-phenanthroline)copper without intramolecular hydrogen migration. Angew. Chem., Int. Ed. Engl. 1997, 36, 2776-2778.
42. Salomons, G. S.; Smets, L. A.; Verwijs-Janssen, M.; Hart, A. A.; Haarman, E. G.; Kaspers, G. J.; Wering, E. V.; Der Does-Van Den Berg, A. V.; Kamps, W. A. Bcl-2 family members in childhood acute lymphoblastic leukemia: Relationships with features at presentation, in vitro and in vivo drug response, and long-term clinical outcome. Leukeumia 1999, 13, 1574-1580.
43. Cassinelli, G.; Supino, R.; Perego, P.; Polizzi, D.; Lanzi, C.; Pratesi, G.; Zunino, F. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int. J. Cancer 2001, 92, 738-747.
44. Kim, R.; Nishimoto, N.; Inoue, H.; Yoshida, K.; Toge, T. An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer. J. Infect. Chemother. 2000, 6, 222-228.
45. Kim, R.; Tanabe, K.; Uchida, Y.; Emi, M.; Inoue, H.; Toge, T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother. Pharmacol. 2002, 50, 343-352.
46. Thomadaki, H.; Scorilas, A. BCL2 family of apoptosis-related genes: Functions and clinical implications in cancer. Crit. Rev. Clin. Lab. Sci. 2006, 43, 1-67.
47. Stegh, A. H.; Kim, H.; Bachoo, R. M.; Forloney, K. L.; Zhang, J.; Schulze, H.; Park, K.; Hannon, G. J.; Yuan, J.; Louis, D. N.; DePinho, R. A.; Chin, L. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev. 2007, 21, 98-111.
48. Nakamoto, K. Infrared and Raman Spectra of Inorganic and Coordination Compounds, 4th ed.; Wiley: New York, 1986.
49. Deacon, G. B.; Phillips, R. J. Relationships between the carbon-oxygen stretching frequences of carboxylato complexes and the type of carboxylate coordination. Coord. Chem. Rev. 1980, 33, 227-250.
50. Efthimiadou, E. K.; Psomas, G.; Sanakis, Y.; Katsaros, N.; Karaliota, A. Metal complexes with the quinolone antibacterial agent N-propyl- norftoxacin: Synthesis, structure, and bioactivity. J. Inorg. Biochem. 2007, 101, 525-535.
51. Hathaway, B. J. Copper. In Comprehensive Coordination Chemistry; Wilkinson, G., Ed.; Pergamon Press: Oxford, 1987; Vol. 5, pp 533-773, and references cited therein.
52. Mukherjee, R. Copper. In Comprehensive Coordination Chemistry II; McCleverty, J. A., Meyer, T. J., Eds.; Elsevier: New York, 2003; Vol. 5, pp 403-553, and references cited therein.
53. Efthimiadou, E. K.; Sanakis, Y.; Katsarou, M.; Raptopoulou, C. P.; Karaliota, A.; Katsaros, N.; Psomas, G. Neutral and cationic mononuclear copper(II) complexes with enrofloxacin: Structure and biological activity. J. Inorg. Biochem. 2006, 100, 1378-1388.
54. Efthimiadou, E. K.; Sanakis, Y.; Raptopoulou, C. P.; Karaliota, A.; Katsaros, N.; Psomas, G. Crystal structure, spectroscopic, and biological study of the copper(II) complex with third-generation quinolone antibiotic Sparfloxacin. Bioorg. Med. Chem. Lett. 2006, 16, 3864-3867.
55. Psomas, G.; Tarushi, A.; Efthimiadou, E. K.; Sanakis, Y.; Raptopoulou, C. P.; Katsaros, N. Synthesis, structure, and biological activity of copper(II) complexes with oxolinic acid. J. Inorg. Biochem. 2006, 100, 1764-1773.
56. Dendrinou-Samara, C.; Psomas, G.; Christophorou, K.; Tangoulis, V.; Raptopoulou, C. P.; Terzis, A.; Kessissoglou, D. P. Structurally diverse of copper(II) herbicide complexes: Mono- and bi-nuclear neutral or cationic complexes. J. Chem. Soc., Dalton Trans. 1996, 3737-3743.
57. Psomas, G.; Dendrinou-Samara, C.; Philippakopoulos, P.; Tangoulis, V.; Raptopoulou, C. P.; Samaras, E.; Kessisoglou, D. P. Cu(II)-herbicide complexes: Structure and bioactivity. Inorg. Chim. Acta 1998, 272, 24-32.
58. Dendrinou-Samara, C.; Psomas, G.; Raptopoulou, C. P.; Kessissoglou, D. P. Copper(II) complexes with phenoxyalkanoic acids and nitrogen donor heterocyclic ligands: Structure and bioactivity. J. Inorg. Biochem. 2001, 83, 7-16.
59. Psomas, G.; Raptopoulou, C. P.; Iordanidis, L.; Dendrinou-Samara, C.; Tangoulis, V.; Kessissoglou, D. P. Structurally diverse copper(II)-carboxylato complexes: Neutral and ionic mononuclear structures and a novel binuclear structure. Inorg. Chem. 2000, 39, 3042-3048.
60. Rodger, A.; Norden, B. Circular Dichroism and Linear Dichroism. Circular Dichroism and Linear Dichroism; Oxford University Press: Oxford, New York, Tokyo, 1997.
61. Son, G. S.; Yeo, J. A.; Kim, M. S.; Kim, S. K.; Holmen, A.; Akerman, B.; Norden, B. Binding mode of norfloxacin to calf thymus DNA. J. Am. Chem. Soc. 1998, 120, 6451-6457.
62. Maheswari, P. U.; Palaniandavar, M. DNA binding and cleavage properties of certain tetrammine ruthenium(II) complexes of modified 1,10 phenenthrolines-effect of hydrogen-bonding on DNA-binding affinity. J. Inorg. Biochem. 2004, 98, 219-230.
63. Schaeffer, P.; Mollet, J.; Aubert, J. P. Catabolic repression of bacterial sporulation. Proc. Natl. Acad. Sci. U.S.A. 1965, 54, 704-711.
64. Ruiz, P.; Ortiz, R.; Perello, L.; Alzuet, G.; Gonzalez-Alvarez, M.; Liu-Gonzalez, M.; Sanz-Ruiz, F. Synthesis, structure, and nuclease properties of several binary and ternary complexes of copper(II) with norfloxacin and 1,10-phenantroline. J. Inorg. Biochem. 2007, 101, 831-840.
65. Zhang, S.; Zhu, Y.; Tu, C.; Wei, H.; Yang, Z.; Lin, L.; Ding, J.; Zhang, J.; Guo, Z. A novel cytotoxic ternary copper(II) complex of 1,10-phenanthroline and L-threonine with DNA nuclease activity. J. Inorg. Biochem. 2004, 98, 2099-2106.
66. Reed, J. C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 1999, 17, 2941-2953.
67. Sellers, W. R.; Fisher, D. E. Apoptosis and cancer drug targeting. J. Clin. Invest. 1999, 104, 1655-1661.
68. Fisher, D. E. Apoptosis in cancer therapy: Crossing the threshold. Cell 1994, 78, 539-542.
69. Kerr, J. F.; Winterford, C. M.; Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994, 73, 2013-2026.
70. Bellamy, C. O.; Malcomson, R. D.; Harrison, D. J.; Wyllie, A. H. Cell death in health and disease: The biology and regulation of apoptosis. Semin. Cancer Biol. 1995, 6, 3-16.
71. McDonnell, T. J.; Meyn, R. E.; Robertson, L. E. Implications of apoptotic cell death regulation in cancer therapy. Semin. Cancer. Biol. 1995, 6, 53-60.
72. Eastman, A. Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Semin. Cancer Biol. 1995, 6, 45-52.
73. Shah, A. M.; Schwartz, G. K. Cell-cycle mediated drug resistance: An emerging concept in cancer therapy. Clin. Cancer Res. 2001, 7, 2168-2181.
74. Wong, E.; Giandomenico, C. M. Current status of platinum-based antitumor drugs. Chem. Rev. 1999, 99, 2451-2466.
75. Kanduc, D.; Mittelman, A.; Serpico, R.; Sinigaglia, E.; Sinha, A. A.; Natale, C.; Santacroce, R.; Di Corcia, M. G.; Lucchese, A.; Dini, L.; Pani, P.; Santacroce, S.; Simone, S.; Bucci, R.; Farber, E. Cell death: Apoptosis versus necrosis (review). Int. J. Oncol. 2002, 21, 165-170.
76. Hill, I. E.; Murray, C.; Richard, J.; Rasquinha, I. Macmanus despite the internucleosomal cleavage of DNA, reactive oxygen species do not produce other markers of apoptosis in cultured neurons. Exp. Neurol. 2000, 162, 73-78.
77. Tsang, S. Y.; Tam, S. C.; Bremner, I.; Burkitt, M. J. Research communication copper-1,10-phenanthroline induces internucleosomal DNA fragmentation in HepG2 cells, resulting from direct oxidation by the hydroxyl radical. Biochem. J. 1996, 317, 13-16.
78. Zhou, H.; Zheng, C.; Zou, G.; Tao, D.; Gong, J. G1-phase specific apoptosis in liver carcinoma cell line induced by copper-1,10-phenanthroline. Int. J. Biochem. Cell Biol. 2002, 34, 678-684.
79. Cai, X.; Pan, N.; Zou, G. Copper-1,10-phenanthroline-induced apoptosis in liver carcinoma Bel-7402 cells associates with copper overload, reactive oxygen species production, glutathione depletion and oxidative DNA damage. BioMetals 2007, 20, 1-11.
80. Russel, A. D. Fundamental principles of activity principles of antimicrobial activity and resistance. In Disinfection, Sterilization and Preservation, 4th ed.; Block, S. S. Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000; pp 31-56.
81. Rossmore, H. W. Nitrogen compounds. Disinfection, Sterilization and Preservation, 5th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000; pp 383-414.
82. Soussy, C. J.; Wolfson, J. S.; Ng, E. Y.; Hooper, D. C. Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob. Agents Chemother. 1993, 37, 2588-2592.
83. Mahamoud, A.; Chevalier, J.; Alibert-Franco, S.; Kern, W. V.; Pages, J. M. Antiobiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J. Antimicrob. Chemother. 2007, 59, 1223-1229.
84. Gellert, M.; Mizuuchi, K.; O'Dea, M. H.; Nash, H. A. DNA gyrase: An enzyme that introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. U.S.A. 1976, 73, 3872-3876.
85. Yeo, J. A.; Cho, T. S.; Kim, S. K.; Moon, H. R.; Jhon, G. H.; Nam, W. Interaction between norfloxacin and single-stranded DNA. Bull. Korean Chem. Soc. 1998, 19, 449-457.
86. Mosmann, T. Rapid colorimetric assay for the cellular growth and survival: application and cytotoxic assays. J. Immunol. 1983, 65, 55.
87. Freshney, R. In Culture of Animal Cells: A Manual of Basic Technique; Alan, R., Ed.; Liss: New York, 1987; p 117.
88. Barry, M. A.; Behnke, C. A.; Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 1990, 40, 2353-2362.
89. Eastman, A.; Barry, M. A. Interaction of trans- diamminedichloroplatinum(II) with DNA: Formation of monofunctional adducts and their reaction with glutathione. Biochemistry 1987, 26, 3303-3307.
90. Chou, R. H.; Huang, H. Restoration of p53 tumor suppressor pathway in human cervical carcinoma cells by sodium arsenite. Biochem. Biophys. Res. Commun. 2002, 293, 298-306.
91. 3+ ions with DNA. J. Inorg. Biochem. 1989, 37, 271-282.
92. Keck, M. V.; Lippard, S. J. Unwinding of supercoiled DNA by platinum ethidium and related complexes. J. Am. Chem. Soc. 1992, 114, 3386-3390.